Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Authors
Keywords
Androgen Receptor, Vorinostat, Abiraterone, Enzalutamide, Androgen Receptor Gene
Journal
Hormones & Cancer
Volume 7, Issue 2, Pages 84-103
Publisher
Springer Nature
Online
2016-01-04
DOI
10.1007/s12672-015-0239-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
- (2015) Samuel J. Vidal et al. CANCER CELL
- Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy
- (2015) Rakesh Singal et al. Clinical Genitourinary Cancer
- A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195
- (2015) B. J. Eigl et al. INVESTIGATIONAL NEW DRUGS
- FDA Approves New Agent for Multiple Myeloma
- (2015) M. P. Fenichel JNCI-Journal of the National Cancer Institute
- miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation
- (2015) Vijay Kumar Eedunuri et al. MOLECULAR ENDOCRINOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents
- (2015) Guanyi Zhang et al. Oncotarget
- FDA Approves New Agent for Multiple Myeloma
- (2015) M. P. Fenichel JNCI-Journal of the National Cancer Institute
- GATA2 as a potential metastasis-driving gene in prostate cancer
- (2015) Yan Ting Chiang et al. Oncotarget
- Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
- (2015) Yuanyuan Qu et al. Scientific Reports
- AR Variant ARv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer
- (2015) Gang Liu et al. NEOPLASIA
- Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1
- (2014) Y. Wang et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
- (2014) Maria Thadani-Mulero et al. CANCER RESEARCH
- Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer
- (2014) C. Geng et al. CANCER RESEARCH
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells
- (2014) William C. Krause et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Androgen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer
- (2014) Jun Qin et al. JOURNAL OF CLINICAL INVESTIGATION
- N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy
- (2014) Sarah K. Martin et al. Molecular Oncology
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer
- (2014) Dayong Wu et al. NUCLEIC ACIDS RESEARCH
- GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex
- (2014) Bin He et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Androgen dynamics and serum PSA in patients treated with abiraterone acetate
- (2014) C J Ryan et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer
- (2014) J.-P. P. Theurillat et al. SCIENCE
- Steroid receptor coactivators: servants and masters for control of systems metabolism
- (2014) Erin Stashi et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Rational design and validation of a Tip60 histone acetyltransferase inhibitor
- (2014) Chunxia Gao et al. Scientific Reports
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
- (2014) Masis Isikbay et al. Hormones & Cancer
- The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer
- (2014) Cynthia C. T. Sprenger et al. Hormones & Cancer
- Nuclear Receptor Coactivators: Master Regulators of Human Health and Disease
- (2013) Subhamoy Dasgupta et al. Annual Review of Medicine
- Targeting Protein-Protein Interaction by Small Molecules
- (2013) Lingyan Jin et al. Annual Review of Pharmacology and Toxicology
- A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
- (2013) N. Mitsiades CANCER RESEARCH
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- An androgen receptor N-terminal domain antagonist for treating prostate cancer
- (2013) Jae-Kyung Myung et al. JOURNAL OF CLINICAL INVESTIGATION
- Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer
- (2013) Andy J. Liedtke et al. JOURNAL OF MEDICINAL CHEMISTRY
- AKR1C3 as a target in castrate resistant prostate cancer
- (2013) Adegoke O. Adeniji et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss
- (2013) Yu Chen et al. NATURE MEDICINE
- Long-Term Survival of Participants in the Prostate Cancer Prevention Trial
- (2013) Ian M. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype
- (2013) J L L Robinson et al. ONCOGENE
- FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants
- (2013) Laura R. Bohrer et al. PROSTATE
- Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression
- (2013) Ayesha A. Shafi et al. STEROIDS
- HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
- (2013) J E Bolden et al. Cell Death & Disease
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- On the Origins of the Androgen Receptor Low Molecular Weight Species
- (2013) Maria Mudryj et al. Hormones & Cancer
- Targeting Pioneering Factor and Hormone Receptor Cooperative Pathways to Suppress Tumor Progression
- (2012) S. Shah et al. CANCER RESEARCH
- Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
- (2012) P.-C. Lin et al. CANCER RESEARCH
- Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors
- (2012) N. Mitsiades et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells
- (2012) Manjula Nakka et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- The Role of SRC-1 in Murine Prostate Carcinogenesis Is Nonessential due to a Possible Compensation of SRC-3/AIB1 Overexpression
- (2012) Jean Ching-Yi Tien et al. International Journal of Biological Sciences
- Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate Cancer
- (2012) Vikash Reebye et al. MOLECULAR ENDOCRINOLOGY
- Discovery of small molecule cancer drugs: Successes, challenges and opportunities
- (2012) Swen Hoelder et al. Molecular Oncology
- Protein–protein interaction inhibitors get into the groove
- (2012) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Germline Mutations inHOXB13and Prostate-Cancer Risk
- (2012) Charles M. Ewing et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterisation of a Tip60 Specific Inhibitor, NU9056, in Prostate Cancer
- (2012) Kelly Coffey et al. PLoS One
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile
- (2012) J. Hrkach et al. Science Translational Medicine
- FOXA1 Promotes Tumor Progression in Prostate Cancer and Represents a Novel Hallmark of Castration-Resistant Prostate Cancer
- (2011) Josefine Gerhardt et al. AMERICAN JOURNAL OF PATHOLOGY
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
- (2011) P N Munster et al. BRITISH JOURNAL OF CANCER
- Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells
- (2011) P. Ostling et al. CANCER RESEARCH
- Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-Based Model of Prostate Cancer Progression
- (2011) Y. Li et al. CANCER RESEARCH
- Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer
- (2011) M. S. Darshan et al. CANCER RESEARCH
- Intratumoral De Novo Steroid Synthesis Activates Androgen Receptor in Castration-Resistant Prostate Cancer and Is Upregulated by Treatment with CYP17A1 Inhibitors
- (2011) C. Cai et al. CANCER RESEARCH
- Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
- (2011) Elahe A. Mostaghel et al. CLINICAL CANCER RESEARCH
- Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
- (2011) Biswajyoti Sahu et al. EMBO JOURNAL
- Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer
- (2011) Diego J Bedoya et al. Expert Review of Anticancer Therapy
- Discovery of (2E)-3-{2-Butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an Orally Active Histone Deacetylase Inhibitor with a Superior Preclinical Profile
- (2011) Haishan Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of the Acetyltransferases p300 and CBP Reveals a Targetable Function for p300 in the Survival and Invasion Pathways of Prostate Cancer Cell Lines
- (2011) F. R. Santer et al. MOLECULAR CANCER THERAPEUTICS
- Small Molecule Inhibition of the Steroid Receptor Coactivators, SRC-3 and SRC-1
- (2011) Ying Wang et al. MOLECULAR ENDOCRINOLOGY
- Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA
- (2011) Dong Wang et al. NATURE
- Regression of Castrate-Recurrent Prostate Cancer by a Small-Molecule Inhibitor of the Amino-Terminus Domain of the Androgen Receptor
- (2010) Raymond J. Andersen et al. CANCER CELL
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer
- (2010) M.-L. Zhu et al. CANCER RESEARCH
- The role of histone deacetylases in prostate cancer
- (2010) Ata Abbas et al. Epigenetics
- Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
- (2010) Bryan J. Schneider et al. INVESTIGATIONAL NEW DRUGS
- Effect of Dutasteride on the Risk of Prostate Cancer
- (2010) Gerald L. Andriole et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
- (2009) L. R. Molife et al. ANNALS OF ONCOLOGY
- Steroid Hormone Transforming Aldo-Keto Reductases and Cancer
- (2009) Trevor M. Penning et al. Annals of the New York Academy of Sciences
- Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)
- (2009) Deborah Bradley et al. CANCER
- Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer
- (2009) D. S. Welsbie et al. CANCER RESEARCH
- Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
- (2009) Qianben Wang et al. CELL
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- The Homeodomain Protein HOXB13 Regulates the Cellular Response to Androgens
- (2009) John D. Norris et al. MOLECULAR CELL
- Prostate-Specific Membrane Antigen Targeted Imaging and Therapy of Prostate Cancer Using a PSMA Inhibitor as a Homing Ligand
- (2009) Sumith A. Kularatne et al. MOLECULAR PHARMACEUTICS
- A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes
- (2009) M Böhm et al. ONCOGENE
- A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland
- (2009) R. P. McMullin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Coactivator selective regulation of androgen receptor activity
- (2009) Irina U. Agoulnik et al. STEROIDS
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
- (2008) W Weichert et al. BRITISH JOURNAL OF CANCER
- Steroid Receptor Coactivator-3/AIB1 Promotes Cell Migration and Invasiveness through Focal Adhesion Turnover and Matrix Metalloproteinase Expression
- (2008) J. Yan et al. CANCER RESEARCH
- Splicing of a Novel Androgen Receptor Exon Generates a Constitutively Active Androgen Receptor that Mediates Prostate Cancer Therapy Resistance
- (2008) S. M. Dehm et al. CANCER RESEARCH
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
- Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
- (2008) Brian Schurko et al. Nature clinical practice. Oncology
- Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70β
- (2007) Yi Peng et al. AMERICAN JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now